Joel M. Reid
About
Joel M. Reid is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Joel M. Reid has authored 270 papers receiving a total of 10.0k indexed citations (citations by other indexed papers that have themselves been cited), including 133 papers in Molecular Biology, 128 papers in Oncology and 59 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Joel M. Reid's work include Cancer therapeutics and mechanisms (61 papers), Neuroblastoma Research and Treatments (53 papers) and Cancer Treatment and Pharmacology (33 papers). Joel M. Reid is often cited by papers focused on Cancer therapeutics and mechanisms (61 papers), Neuroblastoma Research and Treatments (53 papers) and Cancer Treatment and Pharmacology (33 papers). Joel M. Reid collaborates with scholars based in United States, Canada and Switzerland. Joel M. Reid's co-authors include Matthew M. Ames, Sophie J. Bakri, Melissa R. Snyder, José S. Pulido, Susan M. Blaney, Mark Krailo, Brenda J. Weigel, Alex A. Adjei, Ravinder J. Singh and Peter C. Adamson and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Joel M. Reid
264 papers receiving 9.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Joel M. Reid United States | 51 | 4.5k | 3.0k | 1.6k | 1.2k | 1.1k | 270 | 10.0k | ||
| Athanassios P. Kyritsis United States | 48 | 3.2k 0.7× | 2.0k 0.7× | 1.5k 0.9× | 1.0k 0.9× | 2.3k 2.1× | 173 | 7.9k | ||
| Nicolás André France | 50 | 4.1k 0.9× | 2.8k 0.9× | 1.2k 0.7× | 786 0.7× | 744 0.7× | 264 | 8.6k | ||
| Clinton F. Stewart United States | 63 | 6.1k 1.4× | 5.1k 1.7× | 2.1k 1.3× | 2.5k 2.1× | 2.6k 2.4× | 317 | 12.0k | ||
| Alice L. Yu United States | 56 | 6.1k 1.4× | 2.8k 0.9× | 544 0.3× | 3.2k 2.7× | 725 0.7× | 297 | 11.9k | ||
| Nicholas Mitsiades United States | 66 | 10.1k 2.2× | 4.5k 1.5× | 1.1k 0.7× | 276 0.2× | 783 0.7× | 172 | 15.3k | ||
| Johannes Wolff United States | 44 | 2.9k 0.6× | 1.4k 0.5× | 1.2k 0.7× | 1.7k 1.4× | 3.7k 3.4× | 231 | 7.5k | ||
| Didier Decaudin France | 39 | 3.6k 0.8× | 1.8k 0.6× | 403 0.2× | 439 0.4× | 346 0.3× | 148 | 7.0k | ||
| Marcel Kool Germany | 51 | 8.2k 1.8× | 5.5k 1.9× | 937 0.6× | 1.1k 0.9× | 3.6k 3.4× | 215 | 14.4k | ||
| Øystein Fodstad Norway | 68 | 8.1k 1.8× | 5.6k 1.9× | 2.3k 1.4× | 405 0.3× | 482 0.4× | 307 | 14.8k | ||
| Robert J. Lutz United States | 42 | 4.2k 0.9× | 3.2k 1.1× | 579 0.4× | 191 0.2× | 347 0.3× | 116 | 8.7k |
Countries citing papers authored by Joel M. Reid
Since
Specialization
Citations
This map shows the geographic impact of Joel M. Reid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel M. Reid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel M. Reid more than expected).
Fields of papers citing papers by Joel M. Reid
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Joel M. Reid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel M. Reid. The network helps show where Joel M. Reid may publish in the future.
Co-authorship network of co-authors of Joel M. Reid
This figure shows the co-authorship network connecting the top 25 collaborators of Joel M. Reid. A scholar is included among the top collaborators of Joel M. Reid based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel M. Reid. Joel M. Reid is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Lyons, Michael A., Andrés Obregón‐Henao, Karen Rossmassler, et al.. (2024). Use of multiple pharmacodynamic measures to deconstruct the Nix-TB regimen in a short-course murine model of tuberculosis. Antimicrobial Agents and Chemotherapy. 68(5). e0101023–e0101023.
2.
Tarlock, Katherine, Xiaowei Liu, Charles G. Minard, et al.. (2023). Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712. Pediatric Blood & Cancer. 70(12). e30672–e30672.
3.
Wedekind, Mary Frances, Srivandana Akshintala, Brigitte C. Widemann, et al.. (2023). Phase 1/2 study of tiragolumab and atezolizumab in patients with relapsed or refractory SMARCB1 or SMARCA4 deficient tumors.. Journal of Clinical Oncology. 41(16_suppl). TPS10066–TPS10066.
4.
Davis, Kara L., Elizabeth Fox, Joel M. Reid, et al.. (2022). A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412. Clinical Cancer Research. 28(23). 5088–5097.
5.
Reid, Joel M., et al.. (2021). Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside. Endocrinology. 162(12).
6.
Cash, Thomas F., Elizabeth Fox, Xiaowei Liu, et al.. (2021). A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515). Pediatric Blood & Cancer. 68(9). e29065–e29065.
7.
Weaver, Samantha, Cortney A. Turner, Sarah A. Buhrow, et al.. (2021). Chondrocytic and pharmacokinetic properties of Phlpp inhibitors. SHILAP Revista de lepidopterología. 3(3). 100190–100190.
8.
Cole, Kristina A., Sharmistha Pal, Rachel A. Kudgus, et al.. (2019). Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312). Clinical Cancer Research. 26(6). 1213–1219.
9.
Mossé, Yaël P., Elizabeth Fox, David T. Teachey, et al.. (2019). A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921). Clinical Cancer Research. 25(11). 3229–3238.
10.
Nevala, Wendy K., Sarah A. Buhrow, Daniel J. Knauer, et al.. (2016). Antibody-Targeted Chemotherapy for the Treatment of Melanoma. Cancer Research. 76(13). 3954–3964.
11.
Fouladi, Maryam, John P. Perentesis, Lars M. Wagner, et al.. (2014). A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report. Clinical Cancer Research. 21(7). 1558–1565.
12.
Gupta, Shiv K., Ann C. Mladek, Brett L. Carlson, et al.. (2014). Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts. Clinical Cancer Research. 20(14). 3730–3741.
13.
Bender, Julia Glade, Alice Lee, Joel M. Reid, et al.. (2013). Phase I Pharmacokinetic and Pharmacodynamic Study of Pazopanib in Children With Soft Tissue Sarcoma and Other Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report. Journal of Clinical Oncology. 31(24). 3034–3043.
14.
Holkova, Beata, Jeffrey G. Supko, Matthew M. Ames, et al.. (2013). A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2. Clinical Cancer Research. 19(7). 1873–1883.
15.
Bender, Julia Glade, Susan M. Blaney, Scott C. Borinstein, et al.. (2012). A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report. Clinical Cancer Research. 18(18). 5081–5089.
16.
Reid, Joel M., Chad A. Walden, Rui Qin, et al.. (2011). Phase 0 Clinical Chemoprevention Trial of the Akt Inhibitor SR13668. Cancer Prevention Research. 4(3). 347–353.
17.
Malempati, Suman, Brenda J. Weigel, Ashish M. Ingle, et al.. (2011). Phase I/II Trial and Pharmacokinetic Study of Cixutumumab in Pediatric Patients With Refractory Solid Tumors and Ewing Sarcoma: A Report From the Children's Oncology Group. Journal of Clinical Oncology. 30(3). 256–262.
18.
Galanis, Evanthia, Kurt A. Jaeckle, Matthew J. Maurer, et al.. (2009). Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study. Journal of Clinical Oncology. 27(12). 2052–2058.
19.
Molina, Julian R., Scott H. Kaufmann, Joel M. Reid, et al.. (2008). Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data. Clinical Cancer Research. 14(23). 7900–7908.
20.
Patra, Chitta Ranjan, Resham Bhattacharya, Enfeng Wang, et al.. (2008). Targeted Delivery of Gemcitabine to Pancreatic Adenocarcinoma Using Cetuximab as a Targeting Agent. Cancer Research. 68(6). 1970–1978.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Athanassios P. Kyritsis Breakdown of academic impact, for papers by Nicolás André Breakdown of academic impact, for papers by Clinton F. Stewart Breakdown of academic impact, for papers by Alice L. Yu Breakdown of academic impact, for papers by Nicholas Mitsiades Breakdown of academic impact, for papers by Johannes Wolff Breakdown of academic impact, for papers by Didier Decaudin Breakdown of academic impact, for papers by Marcel Kool Breakdown of academic impact, for papers by Øystein Fodstad Breakdown of academic impact, for papers by Robert J. Lutz